Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Generic claim

Maikush structures are mainly used in patents, for protecting compounds related to an invention. The first generic claim, submitted by Markush, was granted in 1924 by the US Patent Office [87-90]. [Pg.70]

Let me emphasize the magnitude of the problem with a simple example. I was once asked to estimate the number of compounds covered by a typical issued patent for a drug of commercial interest. The patent that I selected to analyze was for enalapril, a prominent prodrug ACE inhibitor with a well-established commercial market. Given the parameters as outlined in the patent covering enalapril, an estimation of the total number of compounds included in the generic claim for enalaprilat, the active... [Pg.1]

In any discussion of claims, the terms genus and species will most likely arise. Perhaps a simple example will suffice to illustrate these terms. Suppose I invent a novel process of bleaching pulp employing a halide salt a claim to a method of bleaching by the action of the halide salt would be properly termed a generic claim or genus. On the other hand, if I then claim a chloride salt, this would be a species... [Pg.69]

A prior disclosure in a document or by use destroys the novelty of any claimed invention that is directly and unambiguously derivable there from. The disclosure not only destroys the novelty of specifically mentioned features, but also destroys the novelty of features that are implicit to those skilled in the art (an expert). A specific disclosure of a chemical compound destroys the novelty of a generic claim embracing it. For example, a disclosure of the use of rubber in circumstances where its elastic properties are used, would destroy novelty of the use of an elastic material in general. ... [Pg.884]

Rnd the broadest generic claim, which ordinarily contains a general formula and begins the set of composition-of-matter claims. [Pg.131]

However, these compounds do not exhibit complex I inhibition, but are reported to inhibit the biosynthesis of methionine. The pioneers of the complex I-aminoalkylpyrimidine class are chemists from Ube Industries, who were inspired by a publication of Whitehead and Traverse reporting the diuretic properties of some 4-aminopyrimidine derivatives [5]. Aminoarylalkyl-substituted pyrimidine compounds of the general formula II [6] (Fig. 13.5.3) were first patented in 1988, claiming both insecticidal and fungicidal activity like, for example, rice blast, powdery mildew and downey mildew. Interestingly, diflumetorim (4), Ube s development compound was already generically claimed in this first application but not exemplified either in the text or in the respective tables. [Pg.531]

CLAIMS UNITERM adds enhanced indexing to the chemical and chemically related patent records general terms to describe processes, properties, end products, etc specific compound terms (over 15,000) and chemical fragment terms to describe generic compounds. [Pg.125]

Other expansions of FDA s authority include the Dmg Price Competition and Patent Term Restoration Act of 1984, commonly known as the 1984 Amendments or the Waxman-Hatch Act, which was passed to attain quicker marketing of safe, effective, and less expensive generic dmgs and the Safe Medical Device Amendments of 1990, which was passed to correct perceived weaknesses in the implementation of the 1976 Device Amendments. Congress further expanded FDA authority over nutrition labeling and health and nutrient content claims on food labels with the Nutrition Labeling and Education Act of 1990. [Pg.83]

For any chemical whose identity is claimed as a trade secret, you must submit to EPA two versions of the substantiation form as prescribed in 40 CFR Part 350, published July 29, 1988 In the Federal Register (53 FR 28772). Use the order form In this document to obtain a copy of the rule and substantiation form. One version identifies the chemical the second version does not Identify the chemical specifically, but provides instead a generic identity. Only this latter version will be available to the public. For further explanation of the trade-secret provisions, see the instructions below... [Pg.20]

If listed toxic chemicals are present equal to or above the de minimis cut-off level, your supplier must identify the specific components as they appear in Table II and provide their percentage composition by weight in the mixture or product, tf your supplier maintains that the identity ot a toxic chemical is a trade secret, a generic identity that is structurally descriptive must be supplied on the notice. A maximum concentration level must be provided if your supplier contends that chemical composition information is a trade secret. In either case, you do not need to make a trade secret claim on behalf of your supplier (unless you consider your use of the proprietary mixture a trade secret). On Form R, identify the toxic chemical you are reporting according to its generic name provided in the notification. (See the instructions for Part III, Section 2 on page 18 for more information.) tf the listed chemical is present below the de minimis level, no notification is required. [Pg.31]

If you are making a trade secret claim, you must report the specific chemical identity on your unsanitized Form R and unsanitized substantiation form. Do not report the chemical name on your sanitized Form R and sanitized substantiation form. Include a generic name in Part III, Section 1.4 of your sanitized Form R report. [Pg.37]

Complete Section 1.4 only if you are claiming the specific chemical identity of the toxic chemical as a trade secret and have marked the trade secret block in Part I. Section 1.1 on page 1 of Form R. Enter a generic chemical name that is descriptive of the chemical stmcture. You must limit the generic name to seventy characters (e.g., numbers, letters, spaces, punctuation) or less. Do not enter mixture names in Section 1.4 see Section 2 below. [Pg.37]

Do not complete this section if you have completed Section 1 of Part III. Report the generic name provided to you by your supplier in the section if your supplier Is claiming the chemical identity proprietary or trade secret. Do not answer "yes" in Part I, Section 1.1 on page 1 of the form if you complete this section. You do not need to supply trade secret substantiation forms since it is your supplier who is claiming the material a trade secret. [Pg.37]

CAS number and the chemical name reported on page three must exactly match the listed section 313 CAS number and chemical name. Chemical categories should not be reported with a CAS number. A generic chemical name should only be provided if you are claiming the section 313 chemical identity as trade secret. Chemical names should be taken directly from the list in this document (see pages 40-48). Mixture names are to be entered in Part III, Section 1.4 if that is the sole identification. Mixture names that include the name (or CAS number) of one or more section 313 chemical(s) are not valid. [Pg.91]

Case History In an attempt to protect Lipitor from generic competition, Pfizer sued Ranbaxy in district court asserting, in part, that Ranbaxy infringed upon dependent Claim 6 of U.S. Patent No. 5,273,995 ( 995). [Pg.453]

Case History Takeda, in an attempt to protect Actos from generic competition, sued various generic pharmaceutical manufacturers (collectively Alphapharm) for infringing the claims of U.S. Patent No. 4,687,777 ( 777). At trial, Alphapharm asserted that the compounds covered by the claims of the 777 patent were obvious in view of a prior art compound. The district court found the compounds covered by the claims of the 777... [Pg.460]

Condamin et al. 1976, Stern et al. 2000). Although Condamin et al. (1976) identified oil residues from Mediterranean amphorae, their claim of identifying olive oil is supported by archaeological evidence alone (similar to the case of wine discussed above), and not by the molecular evidence, which is probably limited to the identification of a generic plant oil. Fatty acids have also been found in preserved human soft tissues (Evershed and Connolly 1988, Evershed 1990) and bones (Evershed et al. 1995). [Pg.151]


See other pages where Generic claim is mentioned: [Pg.7]    [Pg.185]    [Pg.94]    [Pg.47]    [Pg.210]    [Pg.822]    [Pg.110]    [Pg.111]    [Pg.9]    [Pg.7]    [Pg.185]    [Pg.94]    [Pg.47]    [Pg.210]    [Pg.822]    [Pg.110]    [Pg.111]    [Pg.9]    [Pg.125]    [Pg.46]    [Pg.60]    [Pg.60]    [Pg.62]    [Pg.312]    [Pg.292]    [Pg.161]    [Pg.357]    [Pg.759]    [Pg.774]    [Pg.799]    [Pg.451]    [Pg.458]    [Pg.923]    [Pg.33]    [Pg.40]    [Pg.319]    [Pg.977]    [Pg.217]    [Pg.382]   
See also in sourсe #XX -- [ Pg.62 ]




SEARCH



Claims

© 2024 chempedia.info